| Delaware (State or other jurisdiction of incorporation) |
000-23186 (Commission File Number) |
62-1413174 (IRS Employer Identification #) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |_| | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |_| | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |_| | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |_| | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c)) |
Item 2.02. Results of Operations and Financial Condition:
On October 20, 2004, the Company issued a news release announcing its financial results for the quarter ended September 30, 2004. A copy of the news release is furnished as exhibit 99.1 hereto and is incorporated by reference into Item 9.01 of Form 8-K.
Item 9.01. Financial Statements and Exhibits:
| Exhibit No. | Description | ||
| 99.1 | Press release dated October 20, 2004 entitled “BioCryst Reports Third Quarter 2004 Financial Results” |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: October 20, 2004 | BioCryst Pharmaceuticals, Inc. | ||||
| By: | /s/ Michael A. Darwin
|
||||
| Michael A. Darwin Chief Financial Officer and Chief Accounting Officer |
|||||
| Item | Description |
| 99.1 | Press release dated October 20, 2004 entitled “BioCryst Reports Third Quarter 2004 Financial Results” |